Table 1.
Analysis of germline gene usage and somatic mutations in VH and VL nucleotide sequences of anti-Aβ antibodies using IMGT/V-QUEST.
| mAb namea | Isotype | Epitope | Immunization | VHb |
R/S FR-IMGTc |
R/S CDR-IMGTc,d |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IGHV gene and allele | IGHD gene and allele | IGHJ gene and allele | FR1 (R/S) | FR2 (R/S) | FR3 (R/S) | CDR1 (R/S) | CDR2 (R/S) | ||||
| WO2 | IgG2a | 2–8 | Aβ1–42 | IGHV8-12*01 (96.6%) | IGHD1-1*01 | IGHJ2*01 (97.7%) | 1/1 | 1/0 | 2/1 | 3/0 | 0/1 |
| 20.1 | IgG2b | 2–8 | Aβ1–42 | IGHV8-12*01 (96.2%) | IGHD2-14*01 | IGHJ3*01 (93.2%) | 5/2 | 0/0 | 1/1 | 0/1 | 0/1 |
| 12B4 | IgG2a | 2–7 | Aβ1–42 | IGHV8-12*01 (96.7%) | IGHD2-13*01 | IGHJ2*01 (100%) | 0/1 | 0/0 | 3/2 | 0/1 | 0/1 |
| 10D5 | IgG1 | 2–7 | Aβ1-28 | IGHV8-12*01 (95.9%) | IGHD1-2*01 | IGHJ2*01 (97.9%) | 1/3 | 0/0 | 4/2 | 2/0 | 0/0 |
| 12A11 | IgG1 | 2–7 | Aβ1–42 | IGHV8-8*01 (98.3%) | IGHD1-1*01 | IGHJ4*01 (90.6%) | 1/1 | 0/0 | 2/0 | 0/1 | 0/0 |
| 20C2 | IgG1 | Conformational | Aβ1–42 ADDL | IGHV8-8*01 (93.1%) | IGHD3-2*01 | IGHJ4*01 (88.9%) | 2/3 | 1/0 | 7/6 | 1/0 | 0/0 |
| 4E2 | IgG1 | Conformational | Aβ1–42 ADDL | IGHV8-8*01 (95.9%) | IGHD1-1*01 | IGHJ2*01 (97.9%) | 1/3 | 0/0 | 5/2 | 1/0 | 0/0 |
| 2D6 | IgG1 | Conformational | Aβ1–42 ADDL | IGHV8-8*01 (95.9%) | IGHD1-1*01 | IGHJ2*01 (97.9%) | 1/3 | 0/0 | 5/2 | 1/0 | 0/0 |
| 2.1 | IgG1 | 1–16 | Aβ1–42 | IGHV8-8*01 (95.2%) | IGHD2-4*01 | IGHJ2*01 (97.9%) | 1/3 | 0/0 | 6/2 | 2/0 | 0/0 |
| Ab9 | IgG2a | 1–16 | Aβ1–42 fibrils | IGHV8-13*1 (99%) | IGHD2-2*01 | IGHJ3*01 (91.7%) | 0/0 | 0/0 | 0/0 | 1/0 | 1/1 |
| mAb namea | VL (V-KAPPA)b |
R/S FR-IMGT |
R/S CDR-IMGTc |
|||||
|---|---|---|---|---|---|---|---|---|
| IGKV gene and allele | IGKJ gene and allele | FR1 (R/S) | FR2 (R/S) | FR3 (R/S) | CDR1 (R/S) | CDR2 (R/S) | CDR3 (R/S) | |
| WO2 | IGKV1-117*01 (94.6%) | IGKJ5*01 (97.4%) | 2/0 | 1/2 | 2/1 | 2/2 | 2/0 | 2/2 |
| 20.1 | IGKV1-117*01 (97.3%) | IGKJ5*01 (100%) | 0/2 | 1/0 | 1/1 | 2/0 | 0/0 | 1/0 |
| 12B4 | IGKV1-117*01 (99.3%) | IGKJ5*01 (100%) | 0/0 | 0/0 | 0/0 | 1/1 | 0/0 | 0/0 |
| 12A11 | IGKV1-117*01 (98.9%) | IGKJ5*01 (100%) | 0/0 | 0/0 | 1/0 | 0/1 | 0/0 | 1/0 |
| 10D5 | IGKV1-117*01 (97.9%) | IGKJ5*01 (97.2%) | 0/0 | 0/0 | 4/0 | 2/0 | 0/0 | 0/0 |
| 20C2 | IGKV1-117*01 (98.3%) | IGKJ5*01 (100%) | 0/1 | 0/1 | 0/1 | 1/0 | 0/0 | 1/0 |
| 4E2 | IGKV1-117*01 (98.9%) | IGKJ5*01 (100%) | 0/0 | 0/0 | 0/2 | 0/1 | 0/0 | 0/0 |
| 2D6 | IGKV1-117*01 (98.9%) | IGKJ5*01 (100%) | 2/0 | 0/0 | 0/0 | 0/1 | 0/0 | 0/0 |
| 2.1 | IGKV1-117*01 (100%) | IGKJ5*01 (100%) | 1/0 | 0/0 | 1/0 | 0/0 | 0/0 | 1/0 |
| Ab9 | IGKV1-110*01 (98.9%) | IGKJ1*01 (100%) | 1/0 | 0/0 | 1/0 | 0/0 | 0/0 | 1/0 |
a
PFA-1 and PFA-2 were not included in the table because no DNA sequences were available in databases for these clones. However, the analysis of there AA sequences with IMGT/DomainGapAlign revealed that both clones are using the IGHV8-12*01 with IGHJ3*01 and the IGKV1-117*01 with IGKJ5*01 genes.
b
Closest germline genes (the value between brackets is the percentage of identity)
c
Somatic hypermutation in complementarity determining region (CDR) and in framework region (FR)–R: replacement mutation; S: silent mutation.
d
VH CDR3 is not included in the analysis.